Order Information
Contact us
Insert title here
Featured Products
HY-10005  |  Flavopiridol
HY-10008  |  SNS-032
HY-10012  |  AZD-5438
HY-10014  |  R547
HY-10032  |  PF 477736
HY-10087  |  Navitoclax
HY-10128  |  ZM-447439
HY-10161  |  Tozasertib
HY-10180  |  MLN8054
HY-10192  |  NVP-TAE 684
HY-10228  |  Motesanib
HY-10249  |  GSK-690693
HY-10355  |  AKT inhibitor VIII
HY-10358  |  MK 2206 (dihydrochloride)
HY-10992  |  AZD-7762
HY-10997  |  PCI-32765
HY-11001  |  PHA-793887
HY-11002  |  CP-466722
HY-11007  |  GNF-2
HY-11009  |  CGP60474


 (Synonyms  PD 0332991)
571190-30-2  Technical Data: Price and Availability of  Cas No:571190-30-2

Cas : 571190-30-2 M.Wt: 447.5327
Cas : 571190-30-2 Formula: C24H29N7O2
Cas : 571190-30-2 Purity: >98 %
Cas : 571190-30-2 Storage: at 20℃ 2 years
Cas : 571190-30-2 Solubility: DMSO: 0.2 mg/mL (Need ultrasonic or warming)
Cas : 571190-30-2 Name: Palbociclib
1g/$395 In-stock
5mg/$50 In-stock
10mg/$70 In-stock
50mg/$90 In-stock
100mg/$110 In-stock
200mg/$140 In-stock
500mg/$260 In-stock
1g Get quote
5g Get quote
>10g Get quote
We match the lowest price on market.
We offer a substantial discount on larger orders,please
inquire via sales@chemexpress.cn
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
Online Inquiry
571190-30-2  Data Sheet:
Introduction of 571190-30-2 :
Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. IC50 & Target: IC50: 11 nM (Cdk4), 16 nM (Cdk6)[1] In Vitro: The IC50 of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser780 in MDA-MB-435 breast carcinoma cells is 66 nM. Palbociclib is equally effective at reducing Rb phosphorylation at Ser795 in this tumor with an IC50 of 63 nM, and similar effects on both Ser780 and Ser795 phosphorylation are obtained in the Colo-205 colon carcinoma[1]. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effectively inhibited by Palbociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC50s are 0.01 ?M, 0.01 ?M, 0.06 ?M, and 0.6 ?M, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC50>10 ?M). The flow cytometry results show that Palbociclib at concentrations between 0 to 1.0 ?M induces G1 arrest in the AN, RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdU incorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation (indicating G1 arrest) in the AN, RY, G401 and NS cell lines, but not in the YM cell line. Palbociclib, even at a concentration of 0.05 ?M, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p<0.05)[2]. In Vivo: Palbociclib (PD 0332991) exhibits significant antitumor efficacy against multiple human tumor xenograft models. In mice bearing Colo-205 colon carcinoma xenografts (p16 deleted), daily p.o. dosing for 14 days with Palbociclib (150 or 75 mg/kg) produces rapid tumor regressions and a corresponding tumor growth delay of ~50 days with >1 log of tumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at doses as low as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise, robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis is apparent at 150 mg/kg and some cell kill is evident at the highest dose[1].
References on 571190-30-2 :

Keywords: buy Palbociclib | Palbociclib Supplier | purchase Palbociclib | Palbociclib cost | Palbociclib manufacturer | order Palbociclib | Palbociclib distributor | Palbociclib structure
buy 571190-30-2 | 571190-30-2 Supplier | purchase 571190-30-2 | 571190-30-2 cost | 571190-30-2 manufacturer | order 571190-30-2 | 571190-30-2 distributor | 571190-30-2 structure
Insert title here
Products are for research use only. Not for human use. We do not sell to patients.           Copyright © 2009 Haoyuan Chemexpress All Rights Reserved
ADDRESS: 6/F, No. 2 Building, No. 720,Cailun Road, Shanghai, P.R.China  
86-21-58998590   FAX: 86-21-53700326, 86-21-58998590   E-mail: sales@chemexpress.cn